Huang 2006.

Methods	Type of study: parallel RCT Type of publication: full Source of funding: not reported Country of origin: China Number of centres: 1 (assumed) Dates of trial enrolment: 05/04 to 05/05 Length of follow‐up: 6 months Number (N) of participants randomised to each arm: 20 in treatment arm/20 in control arm Number (N) of participants analysed (primary outcome) in each arm: 20 in treatment arm/20 in control arm
Participants	Population: AMI, within 24 hours. PCI within 24 hours. Cell transplantation within 2 hours of successful PCI Age, mean (SD) each arm: 57.3 (10.1) years in treatment arm, 56.7 (9.2) years in control arm Sex, % male in each arm: 65% in treatment arm, 70% in control arm Number of diseased vessels: not reported Number of stunned hyperkinetic, etc segments: not reported Time from symptom onset to initial treatment: 6.3 (4.2) hours in treatment arm/6.3 (3.9) hours in control arm Statistically significant baseline imbalances between the groups?: none
Interventions	Intervention arm: BMSC Type of stem cells: bone marrow‐derived stem cells (mononuclear cells‐MNC) Summary of how stem cells were isolated and type and route of delivery: bone marrow aspirate (80 to 140 mL). Cells separated by gradient centrifugation. Cells re‐suspended in heparinised saline (with 0.9% NaCl) prior to transplantation. Intracoronary infusion using a microcatheter (Judkins method) Dose of stem cells: a single dose of 1.8 (4.2) x108/mL cells Timing of stem cell procedure: cells infused within 2 hours of successful PCI Comparator arm: 15 mL of heparinised saline (with 0.9% NaCl)
Outcomes	Primary outcomes: not reported Secondary outcomes: LVEF, LVEDV and infarct size measured by CMR imaging and LV arteriography Outcome assessment points: baseline, 1 week and 6 months Method(s): CMR imaging
Notes	Translated from Chinese (Mandarin)
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	High risk	This Chinese trial was described as randomised but the method of randomisation was not reported
Allocation concealment (selection bias)	High risk	Allocation concealment was not reported
Blinding (performance bias and detection bias) All outcomes	Unclear risk	The control group received a placebo but it was unclear whether they underwent bone marrow aspiration and therefore it was unclear whether they were appropriately blinded. Blinding of clinicians and outcome assessors was not reported
Incomplete outcome data (attrition bias) All outcomes	Low risk	All randomised participants were included in the analysis of clinical and scientific outcomes
Selective reporting (reporting bias)	Unclear risk	All outcomes mentioned in the methods were reported in the results, although it would be difficult to rule out selective reporting
Other bias	Low risk	None reported or identified